These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 36464142)

  • 1. Immunoconjugates and bispecific antibodies: Trends in therapeutic success and commercial focus.
    Kinch MS; Kraft Z; Schwartz T
    Drug Discov Today; 2023 Mar; 28(3):103462. PubMed ID: 36464142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal Antibodies, Bispecific Antibodies and Antibody-Drug Conjugates in Oncohematology.
    Mihăilă RG
    Recent Pat Anticancer Drug Discov; 2020; 15(4):272-292. PubMed ID: 32981510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays.
    Golay J; Introna M
    Arch Biochem Biophys; 2012 Oct; 526(2):146-53. PubMed ID: 22387378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The current status and prospects of antibody engineering for therapeutic use: focus on glycoengineering technology.
    Niwa R; Satoh M
    J Pharm Sci; 2015 Mar; 104(3):930-41. PubMed ID: 25583555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Manipulation of Cell-Type Selective Antibody Internalization by a Guide-Effector Bispecific Design.
    Lee NK; Su Y; Bidlingmaier S; Liu B
    Mol Cancer Ther; 2019 Jun; 18(6):1092-1103. PubMed ID: 30962321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 1, monoclonal antibodies, antibody-drug conjugates and bispecific T-cell engagers.
    Paci A; Desnoyer A; Delahousse J; Blondel L; Maritaz C; Chaput N; Mir O; Broutin S
    Eur J Cancer; 2020 Mar; 128():107-118. PubMed ID: 32037061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations.
    Shim H
    Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32111076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current landscape and future directions of bispecific antibodies in cancer immunotherapy.
    Wei J; Yang Y; Wang G; Liu M
    Front Immunol; 2022; 13():1035276. PubMed ID: 36389699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders.
    Derby L; Czuczman MS
    Future Oncol; 2011 Aug; 7(8):963-79. PubMed ID: 21823892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Progress in the study of Her2-targeted cancer therapeutic antibodies].
    Chang L; Li CH; Gao J
    Yao Xue Xue Bao; 2015 May; 50(5):516-20. PubMed ID: 26234129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bringing Together the Power of T Cell Receptor Mimic and Bispecific Antibodies for Cancer Immunotherapy: Still a Long Way to Go.
    Shivarov V; Blazhev G
    Monoclon Antib Immunodiagn Immunother; 2021 Apr; 40(2):81-85. PubMed ID: 33900820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific antibodies for targeted delivery of anti-cancer therapeutic agents: A review.
    Beishenaliev A; Loke YL; Goh SJ; Geo HN; Mugila M; Misran M; Chung LY; Kiew LV; Roffler S; Teo YY
    J Control Release; 2023 Jul; 359():268-286. PubMed ID: 37244297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracerebral bispecific ligand-antibody conjugate increases survival of animals bearing endogenously arising brain tumors.
    Patrick TA; Kranz DM; Zachary JF; Roy EJ
    Int J Cancer; 1998 Nov; 78(4):470-9. PubMed ID: 9797136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next generation antibody drugs: pursuit of the 'high-hanging fruit'.
    Carter PJ; Lazar GA
    Nat Rev Drug Discov; 2018 Mar; 17(3):197-223. PubMed ID: 29192287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Building blocks for bispecific and trispecific antibodies.
    Wu X; Demarest SJ
    Methods; 2019 Feb; 154():3-9. PubMed ID: 30172007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021.
    Demel I; Bago JR; Hajek R; Jelinek T
    Br J Haematol; 2021 May; 193(4):705-722. PubMed ID: 33216972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody fragments for controlled delivery of therapeutic agents.
    Verhoeyen ME; van der Logt CP; Beggs TS; Davis PJ
    Biochem Soc Trans; 1995 Nov; 23(4):1067-73. PubMed ID: 8654683
    [No Abstract]   [Full Text] [Related]  

  • 18. Affinity chromatography and co-chromatography of bispecific monoclonal antibody immunoconjugates.
    Gupta S; Suresh M
    J Biochem Biophys Methods; 2002 May; 51(3):203-16. PubMed ID: 12088881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homogeneously modified immunoglobulin domains for therapeutic application.
    Liu T; Du J; Luo X; Schultz PG; Wang F
    Curr Opin Chem Biol; 2015 Oct; 28():66-74. PubMed ID: 26117722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioanalytical Challenges in Support of Complex Modalities of Antibody-Based Therapeutics.
    Zhu L; Glick J; Flarakos J
    AAPS J; 2020 Oct; 22(6):130. PubMed ID: 33037499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.